CHRS
NASDAQCoherus Oncology Inc.
Price$1.42-0.05 (-3.40%)
01:30 PM07:45 PM
News · 26 weeks43-56%
2025-12-142026-06-07
Mix1690d
- SEC Filings8(50%)
- Other3(19%)
- Insider2(13%)
- Earnings1(6%)
- Analyst1(6%)
- Offering1(6%)
Latest news
25 items- INSIDERSEC Form 4 filed by Chief Financial Officer Mcmichael Bryan J4 - Coherus Oncology, Inc. (0001512762) (Issuer)
- INSIDERSEC Form 4 filed by President & CEO Lanfear Dennis M4 - Coherus Oncology, Inc. (0001512762) (Issuer)
- SECCoherus Oncology Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Coherus Oncology, Inc. (0001512762) (Filer)
- SECSEC Form DEFA14A filed by Coherus Oncology Inc.DEFA14A - Coherus Oncology, Inc. (0001512762) (Filer)
- PRSolid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth PhaseMarket News Updates News Commentary Breakthrough immunotherapies, ADCs, and precision oncology platforms continue driving major investor attention across the global cancer treatment sectorNEW YORK, May 14, 2026 /CNW/ -- Momentum around solid tumor cancer treatments is picking up fast as new technologies and therapies continue delivering encouraging results across some of the hardest-to-treat cancers. From lung and breast cancer to colorectal, ovarian, and pancreatic cancers, drug developers are making real progress with next-generation immunotherapies, targeted treatments, and antibody-drug conjugates (ADCs). What's getting the industry excited is that many of these newer therapies are showi
- SECSEC Form 10-Q filed by Coherus Oncology Inc.10-Q - Coherus Oncology, Inc. (0001512762) (Filer)
- SECCoherus Oncology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Coherus Oncology, Inc. (0001512762) (Filer)
- PRCoherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update– LOQTORZI® net revenue of $11.8 million in Q1 2026 – – Patient accrual complete for 1L HCC Phase 2 randomized clinical trial for anti-IL27 casdozokitug, timing for data readouts tracking to projections – – Tagmokitug, CCR8 Treg depleter development expands with pharmacological and clinical program differentiation, including dose-responsive immune effects, no off-target binding, acceptable safety – – $167.0 million in quarter-end cash, cash equivalents and marketable securities – – Conference call today at 5:00 p.m. Eastern Daylight Time – REDWOOD CITY, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ:CHRS), today reported financial results for the first quarter
- ANALYSTGuggenheim initiated coverage on Coherus BioSciences with a new price targetGuggenheim initiated coverage of Coherus BioSciences with a rating of Buy and set a new price target of $12.00
- SECSEC Form DEFA14A filed by Coherus Oncology Inc.DEFA14A - Coherus Oncology, Inc. (0001512762) (Filer)
- PRCoherus Oncology to Report First Quarter 2026 Financial Results on May 11, 2026REDWOOD CITY, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ:CHRS), today announced that its first quarter 2026 financial results will be released after market close on Monday, May 11, 2026. Starting at 5:00 p.m. Eastern Time on May 11, 2026, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update. A webcast replay will be available on https://investors.coherus.com following the conclusion of the live conference call. Conference Call Information When: Monday, May 11, 2026, starting at 5:00 p.m. Eastern Standard Time To access the conference call, please pre-register through the followin
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Coherus Oncology Inc.SCHEDULE 13G/A - Coherus Oncology, Inc. (0001512762) (Subject)
- SECSEC Form DEF 14A filed by Coherus Oncology Inc.DEF 14A - Coherus Oncology, Inc. (0001512762) (Filer)
- SECSEC Form DEFA14A filed by Coherus Oncology Inc.DEFA14A - Coherus Oncology, Inc. (0001512762) (Filer)
- SECSEC Form PRE 14A filed by Coherus Oncology Inc.PRE 14A - Coherus Oncology, Inc. (0001512762) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Coherus Oncology Inc.SCHEDULE 13G/A - Coherus Oncology, Inc. (0001512762) (Subject)
- SECSEC Form 10-K filed by Coherus Oncology Inc.10-K - Coherus Oncology, Inc. (0001512762) (Filer)
- SECCoherus Oncology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Coherus Oncology, Inc. (0001512762) (Filer)
- PRCoherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update– LOQTORZI® net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024 – – Reduced secured and convertible debt by 90% from $480 million to $38.8 million over 2024-2025 – – $172.1 million in year ending cash, cash equivalents and marketable securities – – Conference call today at 4:30 p.m. Eastern Standard Time – REDWOOD CITY, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ:CHRS), today reported financial results for the full year and fourth quarter 2025, and provided an overview of recent business highlights. "We are pleased with our progress in 2025, having doubled LOQTORZI sales while completing the transformation from a biosimilars
- PRCoherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026REDWOOD CITY, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ:CHRS), today announced that its full year and fourth quarter 2025 financial results will be released after market close on Monday, March 9, 2026. Starting at 4:30 p.m. Eastern Time on March 9, 2026, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update. A webcast replay will be available on https://investors.coherus.com following the conclusion of the live conference call. Conference Call Information When: Monday, March 9, 2026, starting at 4:30 p.m. Eastern Standard Time To access the conference call, please pre-register
- PRCoherus Oncology to Participate in Upcoming Investor ConferencesREDWOOD CITY, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ:CHRS) today announced that senior management will be presenting during upcoming conferences. The presentations will be accessible via webcast through a link posted on the Investor Events Calendar section of the Coherus Oncology website: https://investors.coherus.com/events-presentations. A replay of the presentation will be available on this same website for approximately 90 days. 46th Annual TD Cowen Healthcare Conference in Boston, on Wednesday, March 4, 2026, at 11:50 a.m. Eastern Daylight TimeCitizens Life Sciences Conference in Miami, on Tuesday, March 10, 2026, at 2:50 p.m. Eastern Daylight Time
- PRCoherus Oncology, Inc. Announces Closing of Public Offering of Common Stock–The Offering was led by healthcare-dedicated investors including Janus Henderson Investors, HBM Healthcare Investments and Samsara BioCapital– REDWOOD CITY, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. ("Coherus" or the "Company") (NASDAQ:CHRS), today announced the closing of an underwritten public offering of 28,600,000 shares of the Company's common stock (the "Offering"). The shares of common stock were sold at a public offering price of $1.75 per share, before underwriting discounts and commissions. All shares in the Offering were sold by the Company. The gross proceeds to Coherus from the Offering were approximately $50.1 million, before deducting underwriting di
- SECCoherus Oncology Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Coherus Oncology, Inc. (0001512762) (Filer)
- SECSEC Form 424B5 filed by Coherus Oncology Inc.424B5 - Coherus Oncology, Inc. (0001512762) (Filer)
- PRCoherus Oncology, Inc. Announces Pricing of Public Offering of Common StockREDWOOD CITY, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. ("Coherus" or the "Company") (NASDAQ:CHRS), today announced the pricing of an underwritten public offering of 28,600,000 shares of the Company's common stock (the "Offering"). The shares of common stock are being sold at a public offering price of $1.75 per share, before underwriting discounts and commissions. All of the shares in the Offering are being sold by the Company. The gross proceeds to Coherus from the Offering are expected to be approximately $50.1 million, before deducting underwriting discounts and commissions and other offering expenses. The Company has granted the underwriters of the Offering a 30
CHRS FAQ
7 questionsWhat does Coherus Oncology Inc. do?
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its product candidate pipeline includes biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar; and...Where does CHRS stock trade?
Coherus Oncology Inc. (CHRS) is listed on NASDAQ.What sector and industry is CHRS in?
Coherus Oncology Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Coherus Oncology Inc. go public?
Coherus Oncology Inc. (CHRS) completed its IPO in 2014.What are analysts saying about CHRS?
Coherus Oncology Inc. has had 8 recent analyst actions on file. The most recent action was from Guggenheim: Buy with a $1200.00 price target on 2026-05-11.What companies are similar to CHRS?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare CHRS side-by-side with any of them on Quantisnow.How can I track CHRS on Quantisnow?
Quantisnow aggregates Coherus Oncology Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CHRS to receive live email and push alerts on every new disclosure.